While this risk hasnt been confirmed in humans, taking semaglutide is not recommended for anyone with a personal or family history of thyroid cancer
However, this higher risk in the unmatched DPP-4i group appeared to be confounded by age, as the unmatched DPP-4i group was on average 7 years older than the GLP-1 RA group
You're desperate for something that actually works
GLP-1RA use was associated with a reduced risk of neurocognitive disorders (e.g., dementia and Alzheimers disease), seizures, thromboembolic disorders, pulmonary hypertension, chronic phlebitis, coagulopathy, and clotting disorders
Additional safety considerations include: Acute pancreatitis risk : Patients should be monitored for severe abdominal pain Gallbladder disease : Including cholelithiasis and cholecystitis Dehydration and acute kidney injury : Particularly with gastrointestinal side effects Hypoglycemia : When used with insulin or sulfonylureas in patients with diabetes Diabetic retinopathy complications : Particularly with semaglutide in patients with pre-existing retinopathy Patients with hypothyroidism should undergo thyroid function monitoring when starting weight loss injections
